Lumitin (conbercept) / Chengdu Kanghong Pharma - LARVOL DELTA

Aqueous-humor biomarkers and real-world efficacy of conbercept for diabetic macular edema: a prospective study in elderly patients. (PubMed, Front Endocrinol (Lausanne)) - "Conbercept produced meaningful anatomical and functional benefits in an elderly DME cohort. Baseline aqueous VEGF and IL-6, while not definitive stand-alone tests, may help identify eyes likely to achieve pronounced anatomical improvement and warrant further investigation as components of a multi-marker predictive panel."

Biomarker • Journal • Real-world evidence • Diabetic Macular Edema • Ophthalmology • IL6

Enhancement of retinal Müller glia's phagocytic activity against hard exudates by conbercept via activation of PPARγ-CD36 axis in diabetic retinopathy. (PubMed, Int J Ophthalmol) - "Conbercept reduces HEs in DR by enhancing Müller glia phagocytosis possibly through activating PPARγ-CD36 axis, which is mediated by inhibition of VEGF signaling. Modulation of Müller glia phagocytic capacity might provide a novel therapeutic strategy to treat DR and DME."

Journal • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Dyslipidemia • Inflammation • Ophthalmology • Retinal Disorders • AVEN • CD36 • IL6 • PPARG • SCARB1

Conbercept combined with retinal photocoagulation significantly improves visual acuity and quality of life in patients with proliferative diabetic retinopathy. (PubMed, Am J Transl Res) - "The combination of Conbercept with retinal photocoagulation significantly improved visual outcomes and reduced postoperative complications in PDR patients, particularly beneficial for patients with advanced age, prolonged disease duration, elevated HbA1c, extended surgical duration, or intraoperative bleeding."

HEOR • Journal • Diabetic Retinopathy • Hematological Disorders • Macular Edema • Ophthalmology • Retinal Disorders

Effect of multiple intravitreal injections of conbercept on the cornea in patients with branch retinal vein occlusion-induced macular edema. (PubMed, Front Med (Lausanne)) - "No adverse reactions, such as endophthalmitis, retinal detachment, or thrombus, were observed in any patient after treatment. Multiple intravitreal injections of conbercept can improve the BCVA and reduce macular edema in patients with BRVO and have no significant effect on the cornea."

Journal • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Thrombosis

Comparative efficacy and safety of anti-VEGF agents with and without Laser therapy for diabetic macular edema: A network meta-analysis. (PubMed, Eur J Ophthalmol) - "ObjectiveTo compare the efficacy and safety of Conbercept, Ranibizumab, and Aflibercept, alone or combined with laser, for the treatment of diabetic macular edema (DME).MethodsWe searched PubMed, Cochrane Library, Embase, Web of Science, CNKI, WanFang, and SinoMed until October 2024 for studies on Conbercept, Ranibizumab, and Aflibercept in DME treatment. For Best-Corrected Visual Acuity (BCVA), both Ranibizumab and Ranibizumab + laser achieved statistically significant gains at 6 and 12 months compared to laser alone, with Ranibizumab + laser consistently ranking highest in efficacy. Safety analysis revealed no significant differences in total adverse event rates across treatments.ConclusionRanibizumab + laser therapy demonstrated the greatest improvement in CRT and BCVA at 3, 6, and 12 months, with no significant differences in adverse events compared to other anti-VEGF options."

Journal • Retrospective data • Review • Diabetic Macular Edema • Ophthalmology

Early combined conbercept and dexamethasone implant therapy for diabetic macular edema. (PubMed, Int Ophthalmol) - "Early combined therapy with dexamethasone implant (Ozurdex) and Conbercept injections offers significant clinical benefits for the treatment of DME during the initial three months of treatment."

Clinical • Journal • Cataract • Diabetic Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Prognostic factors in the treatment of polypoidal choroidal vasculopathy with conbercept: a post hoc analysis of the STAR study. (PubMed, Eye Vis (Lond)) - "In Chinese patients with PCV receiving intravitreal injections of conbercept, baseline characteristics, including age, BCVA, CRT, MRT, number of polypoidal lesions, PED volume, and PED types and morphology, served as predictors of visual and anatomical changes over 48 weeks."

Biomarker • Journal • Retrospective data • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Prognostic factors of conbercept intravitreal injection in the treatment of choroidal neovascularization secondary to pathologic myopia. (PubMed, Eur J Ophthalmol) - "The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR) = 1.303, 95% confidence interval (CI): 1.059-1.603, P = 0.012), baseline BCVA (OR = 15.939, 95% CI: 2.490-102.013, P = 0.003), subfoveal CNV (OR = 0.055, 95% CI: 0.010-0.312, P = 0.001), and well-organized CNV (OR = 0.049, 95% CI: 0.009-0.276, P = 0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV."

Biomarker • Journal • Achromatopsia • Ophthalmology

Metabolic changes in aqueous humor and prognostic implications in diabetic retinopathy patients undergoing cataract surgery with intravitreal anti-VEGF therapy (SOE 2025) - "Purpose: To explore changes in aqueous humor (AH) metabolites and their prognostic implications in non-proliferative diabetic retinopathy (NPDR) patients undergoing cataract surgery (CS) with simultaneous intravitreal anti-VEGF injection. A randomized controlled trial with 48 eyes divided into experimental (CS with intravitreal Conbercept) and control (CS alone) groups... AH metabolite levels remain relatively stable post-CS, but intraoperative anti-VEGF alters its profile. Changes in metabolite levels are associated with prognosis, highlighting the feasibility and necessity of personalized preventive measures for potential post-cataract macular edema (PCME)."

Clinical • Surgery • Cataract • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

Effect of multiple intravitreal injections of conbercept on the cornea in patients with branch retinal vein occlusion-induced macular edema (Frontiers) - "All patients received intravitreal injections of conbercept according to the '3+PRN' regimen and were followed for at least 6 months....The average BCVA was significantly higher at 1, 3, and 6 months after than before the injection (P < 0.05 each). The average central retinal thickness was significantly lower at 1, 3, and 6 months after than before the injection (P < 0.05 each).The number of injections was 3.08 ± 0.27 at the last follow-up. No adverse reactions, such as endophthalmitis, retinal detachment, or thrombus, were observed in any patient after treatment.Multiple intravitreal injections of conbercept can improve the BCVA and reduce macular edema in patients with BRVO and have no significant effect on the cornea."

Retrospective data • Macular Edema • Ophthalmology • Retinal Vein Occlusion

The long-term interactions between Conbercept treatment for RVO-ME and the vitreoretinal interface‌ (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: Wuxi No.2 People’s Hospital; Wuxi No.2 People’s Hospital

New trial

Clinical study on retinal arterial macroaneurysms after anti-VEGF therapy in patients using swept-source optical coherence tomographic angiography (ChiCTR) - P=N/A | N=48 | Recruiting | Sponsor: Eye and ENT Hospital of Fudan University; Eye and ENT Hospital of Fudan University

New trial • Cardiovascular

Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) - P4 | N=58 | Active, not recruiting | Sponsor: Shanghai Eye Disease Prevention and Treatment Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Economic Modelling of Myopia Management: A Systematic Literature Review (ISPOR 2025) - "Key Cost Effectiveness Findings: Atropine formulations: 0.05% was the most cost-effective Atropine concentration for controlling myopia progression compared to 0.025% and 0.01% in children in Hong Kong...Anti-VEGF Treatments: Ranibizumab was more cost-effective than verteporfin photodynamic therapy (vPDT) for treating myopic choroidal neovascularisation (mCNV) in the UK and China. Conbercept was found to be slightly more cost-effective than ranibizumab in China... This SLR highlighted the diverse economic modelling approaches used to assess myopia management strategies, predominantly evaluated in Asian populations. With the increasing prevalence of myopia, its geographic spread and long-term clinical manifestations, there is a need for more comprehensive framework for economic evaluations in myopia."

Review • Ophthalmology

Ocular pharmacokinetics of intravitreal conbercept in a rabbit model following retinal scatter laser photocoagulation. (PubMed, Front Pharmacol) - "Retinal scatter laser photocoagulation shortly before single intravitreal injection of conbercept enabled higher drug clearance and shorter half-life values, resulting in lower exposure in the ocular tissues compared to non-photocoagulated conditions. The distinct ocular pharmacokinetics of intravitreal conbercept observed in a rabbit model through retinal scatter laser photocoagulation is expected to enlighten further studies on investigating the optimal order of the combination of photocoagulation and anti-VEGF agents."

Journal • PK/PD data • Preclinical

Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) - P4 | N=58 | Recruiting | Sponsor: Shanghai Eye Disease Prevention and Treatment Center | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial primary completion date • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Anti-Vascular Endothelial Growth Factor Crunch Syndrome in Proliferative Diabetic Retinopathy. (PubMed, JCEM Case Rep) - "A 33-year-old male individual with proliferative diabetic retinopathy (PDR) received a single intravitreal injection of conbercept (Kanghong Inc., Chengdu, China) for vitreous hemorrhage in his right eye...However, at the 3-month follow-up, visual acuity remained limited to counting fingers. This case highlights crunch syndrome as a rare but serious complication of intravitreal anti-VEGF therapy for PDR, emphasizing the need for careful patient selection and close postoperative monitoring."

Journal • Diabetic Retinopathy • Hematological Disorders • Retinal Disorders

Re: Cheng et al.: Conbercept versus laser for the treatment of infants with zone II retinopathy of prematurity (Ophthalmology. 2024;131:636-638). (PubMed, Ophthalmology) - No abstract available

Journal • Ophthalmology • Retinal Disorders • Retinopathy of Prematurity

Intravitreal conbercept for chronic central serous chorioretinopathy with occult CNV: a retrospective clinical study based on multimodal ophthalmic imaging. (PubMed, Front Med (Lausanne)) - "Baseline CMT, SRF diameter, CNV lesion size, and mean CNV vessel diameter were identified as valuable indicators for assessing treatment response and prognosis. These findings provide important insights for the clinical management and prognostic evaluation of cCSC patients with occult CNV, highlighting the utility of multimodal imaging in assessing treatment outcomes."

Journal • Retrospective data • Ophthalmology • Retinal Disorders

Acute Corneal Epithelial Detachment During Lid Speculum Placement Prior to Intravitreal Injection in a Diabetic Patient: A Case Report. (PubMed, Clin Optom (Auckl)) - "The patient underwent bilateral intravitreal injections of the anti-VEGF agent conbercept...Close observation of corneal epithelial healing is crucial in diabetic patients receiving intravitreal injections, especially those with a recent history of cataract surgery. Careful pre-injection assessment and vigilant post-injection management are essential to mitigate this potential complication."

Journal • Cataract • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy (clinicaltrials.gov) - P=N/A | N=146 | Recruiting | Sponsor: Wang Yusheng | Not yet recruiting ➔ Recruiting

Enrollment open • Retinal Disorders • Retinopathy of Prematurity

Study on the Treatment of Persistent DME with Poor Response to Non-Surgical Therapy through the Combination of Anti-VEGF Drugs and Epiretinal Membrane Peeling Surgery (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: Shanghai Ninth People's Hospital， Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital， Shanghai JiaoTong University

New trial • Diabetic Macular Edema • Ophthalmology • Retinal Disorders

Comparative prospective randomized controlled study of intravitreal Conbercept versus combined intravitreal Conbercept and dexamethasone therapy for the treatment of retinal vein occlusion associated with macular edema (ChiCTR) - P4 | N=70 | Not yet recruiting | Sponsor: Eye and ENT hospital Fudan university; Eye and ENT hospital Fudan university

New P4 trial • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Comparative efficacy of conbercept 3+PRN versus 3+TAE regimens for the treatment of polypoidal choroidal vasculopathy. (PubMed, Int Ophthalmol) - "Both the 3+PRN and 3+TAE conbercept regimens are effective and safe for treating PCV, demonstrating similar improvements in visual and anatomical outcomes. The 3+TAE regimen requires more injections but fewer follow-up visits, which may enhance patient adherence by reducing clinic visits."

Clinical • Journal • Retrospective data • Age-related Macular Degeneration

Two-year results of Conbercept intravitreal injection in proliferative diabetic retinopathy (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders